DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pqqj4d/global_skin) has announced the addition of the "Global Skin Cancer Vaccine Market & Pipeline Insight 2015" report to their offering.
Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.
Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.
Global Skin Cancer Vaccine Market & Pipeline Insight 2015 Report Highlight
- Introduction to Skin Cancer Vaccine
- Global Skin Cancer Vaccine Market Analysis
- Global Skin Cancer Vaccine Pipeline by Company & Phase
- Global Skin Cancer Vaccine Pipeline: 47 Vaccines
- Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines
- Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)
- Personalized Cancer Vaccines: Progress & Possibilities
- Skin Cancer Vaccine Mechanism
- AVAX Technologies
- Immune Design
- NeoStem Oncology
For more information visit http://www.researchandmarkets.com/research/pqqj4d/global_skin